【导读】香港交易所确认与香港证监会就上市申请相关事宜联合致函保荐人，万科企业午后"狂飙" 中国基金报记者 郭玟君 12月10日，港股探底回升，恒生指数收涨0.42%，报25540.78点；恒生科技指数上涨0.48%，报5581.10 点；恒生中国企业指数上涨0.20%，报8954.69点。市场成交额为1933.92亿港元，较前一交易日2102.36 亿港元有所减少。 恒生指数成份股中43只上涨，42只下跌。其中，万洲国际上涨5.01%，海底捞上涨3.45%，石药集团上 涨3.19%，领涨蓝筹。 | 序号 | 名称 | 代码 | 现价 | 涨跌 | 涨跌幅 ▼ | 成交额 | 年初至今 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 万洲国际 | 0288 | 8.590 c | 0.410 | 5.01% | 6.69亿 | 65.77% | | 2 | 海底捞 | 6862 | 14.100 c | 0.470 | 3.45% | 3.77亿 | -6.10% | | 3 | 石药集团 | 1093 | 7.770 c | 0.240 | ...

Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody (JMT206) to conduct clinical trials in the United States, and it has also been approved by the National Medical Products Administration of China for clinical trials in China by November 2025 [1] Group 1: Product Details - JMT206 specifically binds to Activin receptor type IIA (ActRIIA) and IIB (ActRIIB), blocking the binding of Activin A, Myostatin (GDF8), and Growth Differentiation Factor 11 (GDF11) to Activin receptor type II (ActRII) [1] - The product aims to inhibit downstream signaling pathways, reduce muscle loss, and promote skeletal muscle maintenance and growth, achieving muscle gain and fat loss [1] - It also assists GLP-1 receptor agonists in achieving higher quality weight loss effects [1] Group 2: Clinical Application - The approved clinical indication for JMT206 is weight management in obese or overweight individuals with at least one weight-related comorbidity [1] - Preclinical studies have shown that the product exhibits high bioavailability, good efficacy, and safety, indicating a high clinical development value [1]

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has confirmed a joint letter with the Hong Kong Securities and Futures Commission (SFC) to IPO sponsors regarding concerns over the declining quality of recent listing applications and non-compliance issues [8]. Market Performance - On December 10, the Hong Kong stock market saw a rebound, with the Hang Seng Index rising by 0.42% to close at 25,540.78 points, and the Hang Seng Tech Index increasing by 0.48% to 5,581.10 points. The market turnover was HKD 1,933.92 billion, down from HKD 2,102.36 billion the previous trading day [2]. - Among the constituents of the Hang Seng Index, 43 stocks rose while 42 fell. Notable gainers included WH Group, which rose by 5.01%, Haidilao by 3.45%, and CSPC Pharmaceutical by 3.19% [3]. Individual Stock Highlights - WH Group (Code: 0288) closed at HKD 8.590, up 5.01% with a year-to-date increase of 65.77% [4]. - Haidilao (Code: 6862) closed at HKD 14.100, up 3.45%, but has seen a year-to-date decline of 6.10% [4]. - CSPC Pharmaceutical (Code: 1093) closed at HKD 7.770, up 3.19%, with a year-to-date increase of 67.18% [4]. - Alibaba (Code: 9988) had a turnover of HKD 93.22 billion, rising by 1.52% with a year-to-date increase of 89.04% [5]. Vanke Enterprises - Vanke Enterprises experienced a significant surge, with its stock price reaching a maximum increase of 18.56% on December 10, closing at HKD 3.78 per share, up 13.17% for the day [10]. - The company held a bondholders' meeting on December 10 to discuss the extension of its first bond, "22 Vanke MTN004." The company announced that it would not adjust the interest rate of "21 Vanke 02," maintaining it at 3.98% [12]. ETF Launch - The Southern Eastern UK Index Covered Call Option Active ETF is set to launch on December 11 on the Hong Kong Stock Exchange. This ETF will primarily invest in the constituents of the Hang Seng China Enterprises Index and aims to generate income through option premiums [15]. Investment Opportunities - UBS Wealth Management highlighted that the Chinese technology sector represents one of the most significant global opportunities, driven by ample liquidity and expected corporate earnings growth of up to 37% in 2026 [16].

临床前研究显示，该产品表现出较高的生物利用度以及良好的有效性和安全性，具有较高的临床开发价 值。 该产品可同时特异性结合激活素受体IIA型(ActRIIA)与IIB型(ActRIIB)，阻断激活素A(Activin A)、肌抑 素(GDF8)以及生长分化因子11(GDF11)与激活素受体II型(ActRII)的结合，从而抑制下游信号通路的激 活，减少肌肉流失，并促进骨胳肌维持与增长，以达到增肌减脂的效果。同时，该产品亦可协助GLP-1 受体激动剂实现更高质量的减重效果。本次获批的临床适应症为肥胖或超重合并至少一种体重相关合并 症人群的体重管理。 智通财经APP讯，石药集团(01093)发布公告，集团开发的重组全人源抗ActRIIA/IIB单克隆抗体 (JMT206)(该产品)已获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。该产品亦已于 2025年11月获得中华人民共和国国家药品监督管理局批准在中国开展临床试验。 ...

该产品可同时特异性结合激活素受体IIA型(ActRIIA)与IIB型(ActRIIB)，阻断激活素A(ActivinA)、肌抑 素(GDF8)以及生长分化因子11(GDF11)与激活素受体II型(ActRII)的结合，从而抑制下游信号通路的激 活，减少肌肉流失，并促进骨胳肌维持与增长，以达到增肌减脂的效果。同时，该产品亦可协助GLP-1 受体激动剂实现更高质量的减重效果。本次获批的临床适应症为肥胖或超重合并至少一种体重相关合并 症人群的体重管理。 临床前研究显示，该产品表现出较高的生物利用度以及良好的有效性和安全性，具有较高的临床开发价 值。 格隆汇12月10日丨石药集团(01093.HK)宣布，集团开发的重组全人源抗ActRIIA/IIB单克隆抗体 (JMT206)已获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。该产品亦已于2025年11月 获得中华人民共和国国家药品监督管理局批准在中国开展临床试验。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 主席 蔡東晨 重組全人源抗ACTRIIA / IIB單克隆抗體(JMT206) 在美國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的重組全人源抗Act RIIA / IIB單克隆抗體(JMT206)（「該產品」）已獲美國食品 藥品監督管理局(FDA)批准，可在美國開展臨床試驗。該產品亦已於2025年11月獲得中華人 民共和國國家藥品監督管理局批准在中國開展臨床試驗。 該 產 品 可 同 時 特 異 性 結 合 激 活 素 受 體 I IA 型 (A ct R I IA ) 與 I IB 型 (A ct R I IB ) ， 阻 斷 激 活 素 A (Activin A) 、 肌 抑 素 (GDF 8) ...

12月10日，港股低开低走，午后震荡回升集体翻红，截止收盘，恒生指数上涨0.42%报25540.78点，恒 生科技指数上涨0.48%报5581.10点，国企指数涨0.20%报8954.69点。 龙湖集团(00960.HK)：前11个月实现总合同销售金额593.9亿元。 旭辉控股集团(00884.HK)：前11个月累计合同销售金额约151.0亿元。 中国人寿(02628.HK)：截至2025年11月30日，公司总保费超过人民币7000亿元。 柠萌影视(09857.HK)：拟根据购回授权购回股份，不超已发行股份的10%。 盘面上，科网股涨多跌少，美团涨超2%，百度、阿里巴巴、小米涨超1%，哔哩哔哩跌超1%；贵金属股 强势，灵宝黄金涨超9%，潼关黄金、中国白银涨超7%；内房股走高，万科企业一马当先，大幅收涨超 13%，融创中国、中国金茂涨超8%，世茂集团、雅居乐集团涨幅明显；消费电子概念股走低，权重思 摩尔国际跌超7%刷新阶段新低；海运股大幅下跌，太平洋航运跌幅最大，光伏股、影视娱乐股、石油 股、航空股、中资券商股大部分表现低迷。石药集团、李宁涨超3%，东方海外国际跌5.9%，招商银行 跌超3%。今日两只新股上市， ...

Group 1: Market Performance - The Hong Kong Innovation Drug ETF (159570) experienced a slight decline of 0.12% today, with a total trading volume exceeding 1.5 billion yuan [1] - The fund has seen a net inflow of over 1.1 billion yuan yesterday and more than 1 billion yuan today, accumulating a total of over 1.9 billion yuan in the last 20 days [1] - As of December 9, the latest scale of the Hong Kong Innovation Drug ETF reached over 23 billion yuan, leading its peers in the same category [1] Group 2: Federal Reserve and Market Sentiment - The Federal Reserve is expected to announce a 25 basis point rate cut, bringing the federal funds rate to a range of 3.5%-3.75% [3] - There is a notable division within the Federal Open Market Committee (FOMC), leading to the term "hawkish cut" being used, indicating that while a rate cut is expected, further cuts may not be imminent [3] Group 3: Pharmaceutical Sector Developments - The new National Medical Insurance Drug List has added 114 new drugs, including 50 first-class innovative drugs, with an overall success rate of 88%, up from 76% last year [5][8] - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, enhancing coverage for critical areas such as oncology, chronic diseases, and rare diseases [8] - The first commercial insurance innovative drug list has been released, including 19 drugs from 18 companies, aimed at improving access to high-value innovative drugs [6][13] Group 4: Investment Opportunities - The Hong Kong Innovation Drug ETF (159570) is fully invested in innovative drugs, with the top ten constituent stocks accounting for over 74% of its weight [15] - The index has shown a year-to-date increase of over 90%, outperforming other Hong Kong pharmaceutical indices [16] - The ETF's underlying assets are Hong Kong stocks, allowing for T+0 trading, which may attract more investors [16]

公告称，本次申请基于一项Ⅲ期临床试验。该临床试验结果表明，在非糖尿病的肥胖成人受试者中，该 产品可显著降低体重及腰围，改善血糖、血脂及肝酶水平；与诺和诺德开发的司美格鲁肽相比，其有效 性高度一致，安全性特徵相似，且耐受性良好，不良事件发生率略低。基于在疗效、安全性、制剂方面 的优势，该产品具有显著的临床应用价值。 智通财经APP获悉，石药集团(01093)尾盘涨超3%，截至发稿，涨2.92%，报7.75港元，成交额5.15亿港 元。 消息面上，12月8日，石药集团发布公告，公司附属公司石药集团百克(山东)生物制药股份有限公司开 发的司美格鲁肽注射液的第二项上市许可申请已获中华人民共和国国家药品监督管理局受理。本次申报 的适应症为在控制饮食和增加体力活动的基础上对成人超重╱肥胖患者的长期体重管理。此前，该产品 拟用于成人2型糖尿病血糖控制的适应症上市许可申请已于2025年8月获国家药监局受理。 ...

国元国际发布研报称，给予石药集团（01093）"买入"评级，目标价10.11港元，公司积极布局创新药， 研发投入加大，出海成果突出，公司持续高强度投入研发，已构建国际化管线与领先平台，出海成果显 著。尽管短期内成药业务受集采影响承压，但单季度业绩已呈现企稳回升态势，且多款核心创新药临近 关键节点，授权收入成为新增长点，为中长期增长奠定坚实基础。 国元国际主要观点如下： 新药研发投入加大，研发平台优势明显 公司已建成一支逾2000人的国际化研发团队，聚焦于抗肿瘤、精神神经、心血管等治疗领域，拥有8大 研发平台。研发费用41.85亿元，同比增长7.9%，占成药收入27.1%，显示公司持续高强度投入创新，有 近90个产品在临床试验的不同阶段，14款产品已递交上市申请，30余款处于注册临床阶段，为未来收入 结构转型奠定基础，公司计划在未来5年内申报近50款新产品/新适应症上市。 新药研发快速推进，出海成果突出 创新管线加速兑现，授权费收入15.40亿元贡献新增长极，海外授权协议累计潜在里程碑付款超150亿美 元，国际化战略成效初显。SYS6091（HER2ADC）、SYS6010（EGFRADC）、安尼妥单抗（HER ...